Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Treat-to-Target"

Measures of Success

Jason Liebowitz, MD, FACR  |  September 24, 2024

Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.

Treating to Target in Gout: The Trouble with Serum Urate

Samantha C. Shapiro, MD  |  July 21, 2022

New analyses of treat to target in gout may lead to revisions in some guidelines.

Research Roundup: Abstract Data Presented at ACR Convergence 2021

Keri Losavio  |  February 11, 2022

The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD  |  October 13, 2021

The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…

Study Shows Psoriatic Arthritis Impacts Women More Than Men

Mary Beth Nierengarten  |  January 19, 2021

Psoriatic arthritis (PsA) has a higher life impact on women than men, suggesting the need to include life impact as part of the treat-to-target strategy for PsA. This is the finding of a recently published study by Orbai et al., which found female sex independently linked to high PsA life impact.1  The Study The study…

Study Finds Health & Financial Benefits in AxSpA Treat-To-Target Strategy

Thomas R. Collins  |  September 11, 2020

EULAR 2020 e-CONGRESS—In what speakers at the European e-Congress of Rheumatology described as the first treat-to-target and tight control (T2T/TC) strategy trial in axial spondyloarthritis (AxSpA), researchers found such a strategy has both health and financial benefits. In the year-long study—called TICOSPA—centers were randomized to apply either a T2T/TC strategy or care left to the…

9 Steps to Transform Your Rheumatology Practice

Erin Arnold, MD; William Arnold, MD; Gary Crump, MD; David Sikes, MD; Drew Johnson, MS, MBA; & Timothy Harrington, MD  |  August 12, 2020

The ACR position statement on access to care proposes the goal that “… all patients have timely access to expert rheuma­tology care … .”1 The reality is that new and established rheumatology patient wait times are often prolonged, causing delays in necessary diagnosis and treatment. The 2005 and 2015 ACR Workforce studies document intractable and…

Strong Support for Treat-to-Target Strategy in RA Patients

Megan Brooks  |  March 16, 2020

NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations

Gretchen Henkel  |  April 17, 2019

A post-hoc analysis of data from two large clinical trials supports treat-to-target recommendations for patients with rheumatoid arthritis. The research found baseline disease activity was the strongest predictor of a patient’s insufficient response to initial therapy at six months…

  • 1
  • 2
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences